Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area.
BACKGROUND
Experimental evidence suggests that ethanol alters the activity of the endogenous opioid peptide systems in a dose and brain-region dependent manner. These alterations may influence the processes of ethanol reward and reinforcement. Thus, it was the objective of this study to investigate the response of the 3 major opioid peptide systems (endorphins, enkephalins, and dynorphins) to acute ethanol administration, at the level of the midbrain including the ventral tegmental area (midbrain/VTA), a region important for drug, including ethanol reinforcement.


METHODS
Using the in vivo microdialysis technique coupled with specific solid-phase radioimmunoassay for beta-endorphin, met-enkephalin, and dynorphin A(1-8,) changes in the extracellular concentration of theses peptides at the level of midbrain/VTA were determined at distinct time points following the administration of 0.0 (saline), 0.8, 1.2, 1.6, 2.0, and 2.4 g ethanol/kg B.Wt.


RESULTS
A biphasic effect of ethanol on beta-endorphin release was found, with low to medium (1.2, 1.6, and 2.0 g) but not high (2.4 g) doses of ethanol, inducing a significant increase in the dialysate content of beta-endorphin. A late increase in the dialysate content of dynorphin A(1-8) was observed in response to the 1.2 g ethanol dose. However, none of the ethanol doses tested significantly altered the content of met-enkephalin in the dialysate.


CONCLUSIONS
The present findings suggest that the ethanol-induced increase of beta-endorphin release at the level of midbrain/VTA may influence alcohol reinforcement.
Jarjour
Samuel
S
Department of Psychiatry, McGill University, Montréal, Québec, Canada.
Bai
Li
L
Gianoulakis
Christina
C
D000437:Alcoholism / Q000378:metabolism; D000818:Animals; D002492:Central Nervous System Depressants / Q000097:blood / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004399:Dynorphins / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D000431:Ethanol / Q000097:blood / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D008636:Mesencephalon / Q000187:drug effects* / Q000378:metabolism*; D018847:Opioid Peptides / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D017557:Ventral Tegmental Area / Q000187:drug effects* / Q000378:metabolism*; D001615:beta-Endorphin / Q000378:metabolism
D002492:Central Nervous System Depressants; D018847:Opioid Peptides; D010446:Peptide Fragments; D000431:Ethanol; D004744:Enkephalin, Methionine; D001615:beta-Endorphin; D004399:Dynorphins; C026770:dynorphin (1-8)